Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous solution containing the carbohydrate glucose. It is supplied in a sterile liquid form for parenteral administration. The product does not list a specific concentration, and it is marketed in the European Union as a prescription‑only medication. Glucose Viaflo Baxter provides an immediate source of metabolic energy when delivered directly into the bloodstream. It is commonly used in acute care environments.

Glucose Viaflo Baxter is indicated for several clinical situations where rapid provision of carbohydrate energy is required, particularly in hospital settings where oral intake is limited.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to eat. - Energy supplementation during surgery or in intensive care units. - Support for metabolic demands in patients with high glucose utilization. - Use as a carrier solution for compatible intravenous medications.

The safety profile of Glucose Viaflo Baxter reflects the expected physiological response to intravenous glucose administration.

Common: - Transient increase in blood glucose levels. - Mild hyperosmolarity causing temporary thirst. - Local irritation at the infusion site. - Nausea or vomiting if infused rapidly. - Mild headache related to rapid osmotic shifts.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reaction such as rash, itching, or anaphylaxis. - Electrolyte imbalance, particularly hypokalemia, due to insulin‑mediated shifts. - Severe hyperosmolar state causing neurologic impairment.

When using Glucose Viaflo Baxter, clinicians should observe specific precautions to minimize risks and ensure appropriate patient monitoring.

- Verify patient’s baseline blood glucose and adjust infusion rate accordingly. - Monitor blood glucose frequently during and after administration. - Assess renal function, as impaired clearance may affect fluid balance. - Use aseptic technique to prevent catheter‑related infections. - Avoid rapid infusion in patients with known cardiovascular disease. - Consider electrolyte status, especially potassium, before large‑volume administration. - Pregnant or lactating patients should be evaluated individually due to limited safety data.

Glucose Viaflo Baxter may interact with other intravenous agents or systemic medications, influencing glucose homeostasis or infusion compatibility.

Avoid: - Concurrent administration with high‑dose insulin without glucose monitoring. - Mixing with solutions containing calcium or phosphate that can precipitate.

Use with caution: - Co‑infusion with potassium‑containing fluids, as rapid shifts in glucose can affect potassium levels. - Use alongside glucocorticoids, which may exacerbate hyperglycemia. - Administration with beta‑adrenergic agonists, which can increase glucose production.